A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally

PHASE3CompletedINTERVENTIONAL

Enrollment

2,020

Participants

Timeline

Start Date

November 23, 2021

Primary Completion Date

July 19, 2023

Study Completion Date

July 2, 2024

Conditions

Recurrent Herpes Labialis

Interventions

DRUG

Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773

Oral (upper gum area), 50mg, 1 tablet.

DRUG

Placebo

Oral (upper gum area), 1 table.

Trial Locations (1)

Science 37, Culver City